Sort   by:  
 Page size 
TranscriptomicsBortezomib resistance in Mantle Cell Lymphoma (MCL) is associated with plasmacytic differentiation
Bortezomib-induced resistant MCL cell lines (HBL2 BR and JEKO BR) were generated by continuous cultured of corresponding parental cell lines (HBL2 PT and JEKO PT) with increasing bortezomib concentrations The IC50 of bortezomib of BR cell lines was 80 fold higher than the IC50 of the parental clone ...
ORGANISM(S): Homo sapiens 
2010-10-13 | E-GEOD-20915 | biostudies-arrayexpress
TranscriptomicsThe lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia (CLL)
To elucidate effects of tumor host interactions in vivo in CLL, purified tumor cells were obtained concurrently from blood, bone marrow and/or lymph node and analyzed by gene expression profiling. Keywords: RNA Comparision of gene expression profiling in matched pairs of peripheral blood (PB) vs. ...
ORGANISM(S): Homo sapiens 
2010-10-01 | E-GEOD-21029 | biostudies-arrayexpress
TranscriptomicsGenome-wide DNA Methylation Analysis Reveals Novel Targets for Drug Development in Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL) is a mostly incurable malignancy arising from naïve B cells (NBC) in the mantle zone of lymph node follicles. We analyzed genome-wide methylation in MCL patients using the HELP (Hpa II tiny fragment Enrichment by Ligation mediated PCR) assay and found significant aberrancy...
ORGANISM(S): Homo sapiens 
2010-07-30 | E-GEOD-19243 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human cell cancer line treated with bortezomib or Eeyarestatin I (EerI) reveals ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3 only protein NOXA in cancer cells
The ubiquitin-proteasome system (UPS) has recently emerged as a major target for drug development in cancer therapy. The proteasome inhibitor bortezomib has clinical activity in multiple myeloma and mantle cell lymphoma. Here we report that Eeyarestatin I (EerI), a chemical inhibitor that blocks ER-...
ORGANISM(S): Homo sapiens 
2009-02-28 | E-GEOD-14003 | biostudies-arrayexpress
TranscriptomicsThe ERAD inhibitor Eeyarestatin I is a bifunctional compound with an ER localizing domain and a p97/VCP inhibitory group
Protein homeostasis in the endoplasmic reticulum (ER) has recently emerged as a therapeutic target for cancer treatment. Disruption of ER homeostasis results in ER stress, which is a major cause of cell death for cells exposed to the proteasome inhibitor Bortezomib, an anti-cancer drug approved for ...
ORGANISM(S): Homo sapiens 
2010-11-24 | E-GEOD-23849 | biostudies-arrayexpress
Sort   by:  
 Page size